hp 873 has been researched along with Basal Ganglia Diseases in 5 studies
*Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, J; Hartman, HB; Kerman, LL; Kongsamut, S; Roehr, JE; Sandrasagra, A; Tang, L; Weissensee, P | 1 |
| Stahl, SM | 1 |
| Weiden, PJ | 1 |
| Cutler, AJ; Polymeropoulos, MH; Weiden, PJ; Wolfgang, CD | 1 |
| Conway, PG; Corbett, R; Cornfeldt, M; Rush, DK; Strupczewski, JT; Szewczak, MR; Wilmot, CA | 1 |
2 review(s) available for hp 873 and Basal Ganglia Diseases
| Article | Year |
|---|---|
Iloperidone for the treatment of schizophrenia: an updated clinical review.
Topics: Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Hospitalization; Humans; Isoxazoles; Piperidines; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome | 2012 |
Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Female; Humans; Isoxazoles; Long QT Syndrome; Male; Middle Aged; Patient Dropouts; Piperidines; Prospective Studies; Psychotic Disorders; Randomized Controlled Trials as Topic; Schizophrenia; Weight Gain | 2008 |
3 other study(ies) available for hp 873 and Basal Ganglia Diseases
| Article | Year |
|---|---|
Iloperidone binding to human and rat dopamine and 5-HT receptors.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; CHO Cells; Cricetinae; Humans; Isoxazoles; Kinetics; Piperidines; Rats; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Dopamine D4; Receptors, Dopamine D5; Receptors, Serotonin | 1996 |
Role of α1 adrenergic antagonism in the mechanism of action of iloperidone: reducing extrapyramidal symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Basal Ganglia Diseases; Corpus Striatum; Dopamine; Humans; Isoxazoles; Piperidines; Serotonin 5-HT2 Receptor Antagonists | 2013 |
The pharmacological profile of iloperidone, a novel atypical antipsychotic agent.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Basal Ganglia Diseases; Behavior, Animal; Clozapine; Dopamine Antagonists; Haloperidol; Isoxazoles; Male; Mice; Piperidines; Radioligand Assay; Rats; Rats, Wistar; Risperidone; Saimiri; Serotonin Antagonists | 1995 |